Lisata Therapeutics, Inc.

3.13 USD
+0.03 (+0.97%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Lisata Therapeutics, Inc. stock is up 18.11% since 30 days ago. The next earnings date is May 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 51.16% of the previous 42 March’s closed higher than February.

About Lisata Therapeutics, Inc.

Caladrius Biosciences, Inc. focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia.